Inhibrx Biosciences Q1 EPS $(2.15) Misses $(1.79) Estimate
Inhibrx Reports Interim Phase 2 Data For INBRX-106 in First-Line HNSCC
Inhibrx Biosciences To Present Interim Phase 2 HexAgon Study Results For INBRX-106 Plus Keytruda In Head And Neck Cancer On May 11, 2026 Webcast
Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA Plans
Inhibrx Biosciences Highlights 20% ORR for Ozekibart Combo in Late-Line Colorectal Cancer
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue
Inhibrx Biosciences shares are trading higher after reports suggesting that the company may see takeover interest from potential suitors including Merck and Ono Pharmaceutical.
Inhibrx Biosciences Shares Resume Trade
Inhibrx Biosciences Shares Halted On circuit Breaker To The Downside, Stock Now Up 55.22%
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Inhibrx Announces Updated Interim Data From Phase1/2 Ozekibart Combination With Folfiri Evaluation
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Inhibrx Biosciences To Host A Live Webcast Presentation On Tuesday, April 21, 2026, To Provide A Clinical Update From Its Phase 1/2 Study Evaluating Ozekibart In Combination With FOLFIRI In Patients With Locally Advanced Or Metastatic, Unresectable Colorectal Cancer
Stifel Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $150
Inhibrx Biosciences FY25 Review: Catalyst-Driven Hold Ahead Of Key 2026 Data
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Inhibrx Biosciences Q4 EPS $(2.11) Misses $(2.08) Estimate
Inhibrx Announces Participation in Upcoming Scientific Conference
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.